Knight Therapeutics Inc., a pan-American specialty pharmaceutical company, announced that has assumed full commercial activities and is relaunching ONICIT IV (palonosetron) in Brazil and Mexico, through its affiliates in those countries.

In May 2022, Knight and Helsinn Healthcare SA had entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO  in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. In January 2025, Knight and Helsinn announced that they expanded their existing relationship and entered into an exclusive license, distribution and supply agreement for ONICIT IV (palonosetron) in Mexico, Brazil, and other LATAM countries. ONICIT is marketed under the brand name ALOXI in Canada.

Health Technology Insights: Spring Health Proposes Open Industry Benchmark for AI in Mental Health

ONICIT solution for injection is approved and marketed in Brazil and Mexico for the prevention of acute nausea and vomiting associated with the initial and repeated cycles of moderately and highly emetogenic chemotherapy for cancer, and for the prevention of delayed nausea and vomiting associated with the initial and repeated cycles of moderately emetogenic chemotherapy for cancer in adults. In addition, ONICIT is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults, for up to 24 hours after surgery. In Brazil, ONICIT is also indicated for pediatric patients, from 1 month to 17 years of age, for the prevention of acute nausea and vomiting associated with the initial and repeated cycles of emetogenic chemotherapy for cancer, including highly emetogenic chemotherapy.

“We are proud to continue providing patients and health care professionals with advanced treatments like ONICIT to help mitigate the debilitating effects of chemotherapy induced nausea and vomiting,” said Samira Sakhia, President and CEO of Knight. “ONICIT is synergistic with our existing oncology portfolio and will continue leveraging the existing commercial and medical footprint.”

Health Technology Insights: Qualifacts and OPEN MINDS Strengthen Partnership to Boost Growth

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – GlobeNewswire